Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P- Y Dietrich

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
Revue Medicale Suisse|July 5, 2011
[Diversity and individualization of cancer treatment]P-Y Dietrich
Revue Neurologique|April 2, 2002
[Antitumor immune response: what are the roles for gliomas?]P Y Dietrich
La Revue Du Praticien|May 15, 1992
[Renal cell cancer: oncogenes and tumor suppressor genes]P Y Dietrich, J P Droz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndromeP-Y Dietrich, M A Duchosal
Progress in Brain Research|September 8, 2001
Immune escape of gliomasP R Walker, P Y Dietrich
Hematology/Oncology Clinics of North America|April 1, 1993
Acute leukemia after the treatment of Hodgkin's diseaseM Henry-Amar, P Y Dietrich
Dermatology (Basel, Switzerland)|January 10, 2008
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva)J Lübbe, I Masouyé, P Y Dietrich
Revue Medicale Suisse|July 9, 2015
[Maintenance chemotherapy: futility or utility?]A Friedlaender, E Fernandez, P-Y Dietrich
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1997
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes backP R Walker, P Saas, P Y Dietrich
Current Opinion in Immunology|October 31, 1998
Tumor expression of Fas ligand (CD95L) and the consequencesP R Walker, P Saas, P Y Dietrich
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
Revue Medicale Suisse|July 5, 2011
[Diversity and individualization of cancer treatment]P-Y Dietrich
Revue Neurologique|April 2, 2002
[Antitumor immune response: what are the roles for gliomas?]P Y Dietrich
La Revue Du Praticien|May 15, 1992
[Renal cell cancer: oncogenes and tumor suppressor genes]P Y Dietrich, J P Droz
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2008
Bevacizumab therapy before autologous stem-cell transplantation for POEMS syndromeP-Y Dietrich, M A Duchosal
Progress in Brain Research|September 8, 2001
Immune escape of gliomasP R Walker, P Y Dietrich
Hematology/Oncology Clinics of North America|April 1, 1993
Acute leukemia after the treatment of Hodgkin's diseaseM Henry-Amar, P Y Dietrich
Dermatology (Basel, Switzerland)|January 10, 2008
Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva)J Lübbe, I Masouyé, P Y Dietrich
Revue Medicale Suisse|July 9, 2015
[Maintenance chemotherapy: futility or utility?]A Friedlaender, E Fernandez, P-Y Dietrich
Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1997
Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes backP R Walker, P Saas, P Y Dietrich
Current Opinion in Immunology|October 31, 1998
Tumor expression of Fas ligand (CD95L) and the consequencesP R Walker, P Saas, P Y Dietrich
Pageof 10